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To clarify genome-wide DNA methylation proﬁles during multi-
stage renal carcinogenesis, bacterial artiﬁcial chromosome array-
based methylated CpG island ampliﬁcation (BAMCA) was
performed. Non-cancerous renal cortex tissue obtained from pa-
tients with clear cell renal cell carcinomas (RCCs) (N) was at the
precancerous stage where DNAhypomethylation and DNA hyper-
methylation on multiple bacterial artiﬁcial chromosome (BAC)
clones were observed. By unsupervised hierarchical clustering
analysis based on BAMCA data for their N, 51 patients with clear
cell RCCs were clusteredintotwo subclasses, Clusters AN (n 5 46)
and BN (n 5 5). Clinicopathologically aggressive clear cell RCCs
were accumulated in Cluster BN, and the overall survival rate of
patients in Cluster BN was signiﬁcantly lower than that of patients
in Cluster AN. By unsupervised hierarchical clustering analysis
based on BAMCA data for their RCCs, 51 patients were clustered
into two subclasses, Clusters AT (n 5 43) and BT (n 5 8). Clini-
copathologically aggressive clear cell RCCs were accumulated in
Cluster BT, and the overall survival rate of patients in Cluster BT
was signiﬁcantly lower than that of patients in Cluster AT. Multi-
variate analysis revealed that belonging to Cluster BT was an in-
dependent predictor of recurrence. Cluster BN was completely
included in Cluster BT, and the majority of the BAC clones that
signiﬁcantly discriminated Cluster BN from Cluster AN also dis-
criminated Cluster BT from Cluster AT. In individual patients,
DNA methylation status in N was basically inherited by the cor-
responding clear cell RCC. DNA methylation alterations in the
precancerous stage may generate more malignant clear cell RCCs
and determine patient outcome.
Introduction
It is known that DNA hypomethylation results in chromosomal in-
stability as a result of changes in chromatin structure and that DNA
hypermethylation of CpG islands silences tumor-related genes in co-
operation with histone modiﬁcation in human cancers (1–5). Accu-
mulating evidence suggests that alterations of DNA methylation are
involved even in the early and the precancerous stages (6,7). On the
other hand, in patients with cancers, aberrant DNA methylation is
signiﬁcantly associated with poorer tumor differentiation, tumor ag-
gressiveness and poor prognosis (6,7). Therefore, alterations of DNA
methylation may play a signiﬁcant role in multistage carcinogenesis
and can become an indicator for carcinogenetic risk estimation and
a biological predictor of poor prognosis in patients with cancers. Re-
cently developed array-based technology for accessing genome-
wide DNA methylation status (8–10) is now mainly used to identify
tumor-related genes silenced by DNA methylation in human cancers.
Subclassiﬁcation of cancers based on DNA methylation status, which
may reﬂect the distinct epigenetic pathways of carcinogenesis,
and DNA methylation proﬁles, which could become the optimum
indicator for carcinogenetic risk estimation and prediction of patient
outcome, should be further explored in each organ using array-based
approaches.
With respect to renal carcinogenesis, we have reported that accu-
mulation of DNA methylation on C-type CpG islands occurs in
a cancer-speciﬁc but not age-dependent manner (11), even in non-
cancerous renal tissue samples obtained from patients with clear cell
renal cell carcinomas (RCCs) (6,7,12). Although precancerous con-
ditions in the kidney have been rarely described, from the viewpoint
of altered DNA methylation, non-cancerous renal tissues obtained
from patients with clear cell RCCs are considered to already be at
the precancerous stage in spite of showing no remarkable histological
changes and lacking association with chronic inﬂammation and per-
sistent infection with viruses or other pathogenic microorganisms.
Surprisingly, accumulation of DNA methylation on C-type CpG is-
lands in such non-cancerous renal tissues has been shown to be sig-
niﬁcantly correlated with higher histological grades of the
corresponding clear cell RCCs developing in individual patients
(6,7,12). However, since in the previous study we examined DNA
methylation status on only a restricted number of CpG islands (12),
we were unable to conclude that genome-wide DNA methylation alter-
ations in precancerous conditions generate more malignant RCCs. In the
previous study, accumulation of DNA methylation on C-type CpG
islands in clear cell RCCs themselves was signiﬁcantly correlated with
tumor aggressiveness and poorer patient outcome (12). However, we
were unable to conclude that the examined C-type CpG islands are
the optimum prognostic indicator for patients with clear cell RCCs.
In this study, in order to clarify genome-wide DNA methylation
proﬁles during multistage renal carcinogenesis, we performed bacte-
rial artiﬁcial chromosome array-based methylated CpG island ampli-
ﬁcation (BAMCA) (13–15) using a microarray of 4361 bacterial
artiﬁcial chromosome (BAC) clones (16) in normal renal cortex tissue
samples, non-cancerous renal cortex tissue samples obtained from
patients with clear cell RCC and the corresponding clear cell RCCs.
Materials and methods
Patients and tissue samples
Paired specimens of cancerous tissue (T1–T51) and corresponding non-
cancerous renal cortex tissue showing no remarkable histological changes
(N1–N51) were obtained from materials surgically resected from 51 patients
(RCC1–RCC 51) with primary clear cell RCC. These patients did not receive
preoperative treatment and underwent nephrectomy in 1999–2006 at the
National Cancer Center Hospital, Tokyo, Japan. There were 34 men and 17
women with a mean (±SD) age of 59 ± 10 years (range 31–81 years). His-
tological diagnosis was made in accordance with the World Health Organi-
zation classiﬁcation (17). All the tumors were graded on the basis of
Abbreviations: BAC, bacterial artiﬁcial chromosome; BAMCA, bacterial ar-
tiﬁcial chromosome array-based methylated CpG island ampliﬁcation; RCC,
renal cell carcinoma; TNM, tumor–node–metastasis.
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tumor–node–metastasis (TNM) classiﬁcation (19). The criteria for macro-
scopic conﬁguration of RCC (12) followed those established for hepatocel-
lular carcinoma: type 3 (contiguous multinodular type) hepatocellular
carcinomas show poorer histological differentiation and a higher incidence
of intrahepatic metastasis than type 1 (single nodular type) and type 2 (single
nodular type with extranodular growth) hepatocellular carcinomas (20). The
presence or absence of vascular involvement was examined microscopically
on slides stained with hematoxylin–eosin and elastica van Gieson. The pres-
ence or absence of tumor thrombi in the main trunk of the renal vein was
examined macroscopically. RCC is usually encapsulated by a ﬁbrous capsule
and well demarcated and hardly ever contains ﬁbrous stroma between cancer
cells (panel Tin Figure 1A). Therefore, wewere able to obtain cancer cells of
high purity from surgical specimens, avoiding contamination with both non-
cancerous epithelial cells and stromal cells.
For comparison, eight normal renal cortex tissue samples (C1–C8) were
obtained from materials surgically resected from eight patients without any
primary renal tumor. These patients included ﬁve men and three women with
a mean (±SD) age of 61 ± 12 years (range 47–81 years). Six of these patients
underwent nephroureterectomy for urothelial carcinomas of the ureter, and the
other two patients underwent nephrectomy with resection of retroperitoneal
sarcoma around the kidney.
High-molecular weight DNA from these fresh frozen tissue samples was
extracted using phenol–chloroform, followed by dialysis. Because DNA meth-
ylation status is known to be organ speciﬁc (21), the reference DNA for
analysis of the developmental stages of clear cell RCC should be obtained
from the renal cortex and not from other organs or peripheral blood. Therefore,
a mixture of normal renal cortex tissue DNA obtained from six male patients
(C9–C14) without any primary renal tumor was used as a reference for anal-
yses of male test DNA samples, and a mixture of normal renal cortex tissue
DNA obtained from three female patients (C15–C17) without any primary
renal tumor was used as a reference for analyses of female test DNA samples.
This study was approved by the Ethics Committee of the National Cancer
Center, Tokyo, Japan.
BAMCA
DNA methylation status was analyzed by BAMCA using a custom-made
array (MCG Whole Genome Array-4500) harboring 4361 BAC clones
throughout chromosomes 1–22 and X and Y (16), as described previously
(13–15). Brieﬂy, 5 lg aliquots of test or reference DNA were ﬁrst digested
with 100 U of methylation-sensitive restriction enzyme SmaI and subse-
quently with 20 U of methylation-insensitive XmaI. Adapters were ligated
to XmaI-digested sticky ends, and polymerase chain reaction was performed
with an adapter primer set. Test and reference polymerase chain reaction
Fig. 1. DNA methylation alterations during multistage renal carcinogenesis. (A) Microscopic view of normal renal cortex tissue obtained from a patient without
any primary renal tumor (C), non-cancerous renal cortex tissue obtained from a patient with clear cell RCC (N) and clear cell RCC (T). N shows no remarkable
histological changes compared with C, i.e. no cytological or structural atypia is evident in N. Since T hardly ever contains ﬁbrous stroma between cancer cells, we
were able to obtain cancer cells of high purity, avoiding contamination with stromal cells. Hematoxylin–eosin staining. Original magniﬁcation  20. (B) Scanned
array images yielded by BAMCA in C, N and T. Test and reference DNA labeled with Cy3 and Cy5 was cohybridized, respectively. (C) Scattergrams of the signal
ratios (test signal:reference signal) yielded by BAMCA in C, N and T. In all eight C samples (C1–C8), the signal ratios of 97% of BAC clones were between 0.67
and 1.5 (red bars). Therefore, in N and T, DNA methylation status corresponding to a signal ratio of ,0.67 and .1.5 was deﬁned as DNA hypomethylation and
DNAhypermethylationoneachBAC clone comparedwith C, respectively.EventhoughNdidnot showany remarkablehistologicalchangescomparedwith C[panels
C and N in (A)], many BAC clones showed DNA hypomethylation or hypermethylation. In T, more BAC clones showed DNA hypomethylation or hypermethylation,
and the degree of DNA hypomethylation and hypermethylation, i.e. deviation of the signal ratio from 0.67 or 1.5, was increased in comparison with N.
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215products were labeled by random priming with Cy3- and Cy5-dCTP (GE
Healthcare, Buckinghamshire, UK), respectively, using a BioPrime array
CGH genomic labeling system (Invitrogen, Carlsbad, CA) and precipitated
together with ethanol in the presence of Cot-I DNA. The mixture was ap-
plied to array slides and incubated at 43C for 72 h. Arrays were scanned
with a GenePix Personal 4100A (Axon Instruments, Foster City, CA) and
analyzed using GenePix Pro 5.0 imaging software (Axon Instruments) and
Acue 2 software (Mitsui Knowledge Industry, Tokyo, Japan). The signal
ratios were normalized in each sample to make the mean signal ratios of
all BAC clones 1.0.
Statistics
Differences in the average number of BAC clones that showed DNA methyl-
ation alterations (DNA hypomethylation and hypermethylation) between non-
cancerous renal cortex tissue samples obtained from patients with clear cell
RCCs, and the clear cell RCCs themselves, were analyzed using the Mann–
Whitney U-test. Differences at P , 0.05 were considered signiﬁcant. Two-
dimensional unsupervised hierarchical clustering analysis of the patients with
clear cell RCCs and the BAC clones based on the signal ratios (test signal:
reference signal) obtained by BAMCA in non-cancerous renal cortex tissue
samples and those in clear cell RCCs were performed using the Expressionist
software program (Gene Data, Basel, Switzerland). Correlations between the
subclassiﬁcation of patients with clear cell RCCs yielded by the unsupervised
hierarchical clustering based on DNA methylation status of non-cancerous
renal cortex tissue samples (Clusters AN and BN) and clinicopathological
parameters of the corresponding clear cell RCCs were analyzed using chi-
square test. Correlations between the subclassiﬁcation of patients yielded by
the unsupervised hierarchical clustering based on DNA methylation status in
clear cell RCCs (Clusters ATand BT) and clinicopathological parameters of the
RCCs themselves were analyzed using chi-square test. Survival curves of
patients belonging to Clusters AN versus BN and Clusters AT versus BT were
calculated by the Kaplan–Meier method, and the differences were compared
by the Log-rank test. The Cox proportional hazards multivariate model was
used to examine the prognostic impact of the subclassiﬁcationofpatientsbased
on the DNA methylation status of their clear cell RCCs (Clusters AT and BT),
histological grade, macroscopic conﬁguration, vascular involvement and renal
vein tumor thrombi.Differences at P , 0.05were consideredsigniﬁcant.BAC
clones whose signal ratios were signiﬁcantly different between Clusters AN
and BN and Clusters AT and BT were each identiﬁed by Wilcoxon test
(P , 0.01).
Results
DNA methylation alterations in samples of both cancerous and non-
cancerous renal cortex tissue obtained from patients with clear cell
RCCs
Figure 1B and C shows examples of scanned array images and scatter-
grams of the signal ratios (test signal:reference signal), respectively,
fornormalrenal cortextissuefrom apatient without anyprimary renal
tumor and both non-cancerous renal cortextissue and cancerous tissue
from a patient with clear cell RCC. In all normal renal cortex tissue
samples (C1–C8), the signal ratios of 97% of the BAC clones were
between 0.67 and 1.5 (red bars in Figure 1C). Therefore, in non-
cancerous renal cortex tissue obtained from patients with clear cell
RCCs and the clear cell RCCs themselves, DNA methylation status
corresponding to a signal ratio of ,0.67 and .1.5 was deﬁned as
DNA hypomethylation and DNA hypermethylation of each BAC
clone compared with normal renal cortex tissue, respectively. In sam-
ples of non-cancerous renal cortex tissue obtained from patients with
clear cell RCCs (N1–N51), many BAC clones showed DNA hypome-
thylation or DNA hypermethylation (panel N of Figure 1C). In clear
cell RCCs themselves (T1–T51), more BAC clones showed DNA
hypomethylation or DNA hypermethylation, and the degree of DNA
hypomethylation and DNA hypermethylation, i.e. deviation of the
signal ratio from 0.67 or 1.5, was increased in comparison with
non-cancerous renal cortextissue samples obtained from patients with
clear cell RCCs (panel Tof Figure 1C). The average number of BAC
clones showing DNA hypomethylation increased signiﬁcantly
from non-cancerous renal cortex tissue samples obtained from pa-
tients with clear cell RCCs (93 ± 75) to clear cell RCCs (142 ± 74,
P 5 0.0002). The average number of BAC clones showing DNA
hypermethylation also increased signiﬁcantly in a similar manner
(83 ± 73–123 ± 786, P 5 0.004).
Unsupervised hierarchical clustering of patients with clear cell RCCs
based on DNA methylation status of non-cancerous renal cortex tissue
samples
By two-dimensional unsupervised hierarchical clustering analysis
based on BAMCA data (signal ratios) for non-cancerous renal cortex
tissue samples, the 51 patients with clear cell RCCs were clustered
into two subclasses, Clusters AN and BN, which contained 46 and
5 patients, respectively (Figure 2A).
Table IA shows the clinicopathological parameters of clear cell
RCCs of patients belonging to Clusters AN and BN. The corre-
sponding clear cell RCCs of patients in Cluster BN showed more
frequent macroscopically evident multinodular (type 3) growth,
vascular involvement and renal vein tumor thrombi and showed
higher pathological TNM stages than those in Cluster AN. Figure
2B shows the Kaplan–Meier survival curves of patients belonging
to Clusters AN and BN.T h ep e r i o dc o v e r e dr a n g e df r o m8 8t o2 8 0 1
days (mean, 1679 days). Three (60%) of the patients in Cluster BN
died of recurrent RCC, whereas only one (2%) of the patients
in Cluster AN died. The overall survival rate of patients in Cluster
BN was signiﬁcantly lower than that of patients in Cluster AN
(Figure 2B).
Although Cluster AN was divided into three subclusters, AN1
(n 5 3), AN2 (n 5 19) and AN3 (n 5 24) (Figure 2A), there were
no signiﬁcant correlations between these subclusters and any of the
clinicopathological parameters examined (data not shown). Even
when unsupervised hierarchical clustering was performed separately,
based not on signal ratios but on the presence or absence of DNA
hypomethylation and the presence or absence of DNA hypermethy-
lation, the majority of patients in Cluster BN were clustered into the
same subclass (supplementary Figure S1A and B is available at
Carcinogenesis Online).
Wilcoxon test (P , 0.01) revealed that the signal ratios of 1143
BAC clones in non-cancerous renal cortex tissue differed signiﬁcantly
between Clusters AN and BN: e.g. patients belonging to Cluster BN
were completely discriminated from patients in Cluster AN by the
DNA methylation status of samples of non-cancerous renal cortex
tissue for representative BAC clones (Cluster AN versus Cluster BN
in Figure 3A) out of the 1143 BAC clones.
Unsupervised hierarchical clustering based on DNA methylation
status of clear cell RCCs
Two-dimensional unsupervised hierarchical clustering analysis based
on BAMCA data (signal ratios) for clear cell RCCs was able to group
51 patients into two subclasses, Clusters AT and BT, which contained
43 and eight patients, respectively (Figure 2C).
Table IB shows the clinicopathological parameters of clear cell
RCCs of patients belonging to Clusters AT and BT. Clear cell RCCs
in Cluster BT showed more frequent vascular involvement and renal
vein tumor thrombi and showed higher pathological TNM stages than
those in Cluster AT. Figure 2D shows the Kaplan–Meier survival
curves of patients belonging to Clusters AT and BT. Three (37.5%)
of the patients in Cluster BT died due to recurrent RCCs, whereas only
one (2.3%) of the patients in Cluster AT died. The overall survival rate
of patients in Cluster BT was signiﬁcantly lower than that of patients
in Cluster AT (Figure 2D). Multivariate analysis revealed that our
clustering was a predictor of recurrence and was independent of his-
tological grade, macroscopic conﬁguration, vascular involvement and
renal vein tumor thrombi (Table II).
Although Cluster ATwas divided into four subclusters, AT1 (n 5 8),
AT2 (n 5 12), AT3 (n 5 13) and AT4 (n 5 10) (Figure 2B), there were
no signiﬁcant correlations between these subclusters and any of the
clinicopathological parameters examined (data not shown). Even
when unsupervised hierarchical clustering was performed sepa-
rately, based not on signal ratios but on the presence or absence
of DNA hypomethylation and the presence or absence of DNA
hypermethylation, the majority of patients in Cluster BT were clus-
tered into the same subclass (supplementary Figure S1C and D is
available at Carcinogenesis Online).
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216Wilcoxon test (P , 0.01) revealed that the signal ratios of 1111
BAC clones in clear cell RCCs were differed signiﬁcantly be-
tween Clusters ATand BT. In particular, patients belonging to Cluster
BT were completely discriminated from patients belonging to Clu-
ster AT based on the DNA methylation status of 14 BAC clones
(Cluster AT versus Cluster BT in Figure 3A). In other words, DNA
methylation status of the 14 BAC clones was able to determine
whether or not patients in this cohort belonged to Cluster BT, a signif-
icant prognostic indicator, with a sensitivity and speciﬁcity of 100%
using the cutoff values shown in Figure 3A and supplementary Table
Fig. 2. Two-dimensional unsupervised hierarchical clustering analysis based on BAMCA data (signal ratios) in non-cancerous renal cortex tissue samples
showing no remarkable histological changes (A) and clear cell RCCs (C) and Kaplan–Meier survival curves of patients with clear cell RCCs (B and D). (A) Fifty-
one patients with clear cell RCC were hierarchically clustered into two subclasses, Clusters AN (n 5 46) and BN (n 5 5), based on DNA methylation status of
their non-cancerous renal cortex tissue samples. DNA hypomethylation, normomethylation (DNA methylation status corresponding to a signal ratio of between
0.67 and 1.5) and hypermethylation on each BAC clone are shown in green, black and red, respectively. The signal ratio is shown in the color range maps. The
cluster trees for patients and BAC clones are shown at the top and left of the panel, respectively. (B) The overall survival rate of patients in Cluster BN (square)
deﬁned on the basis of DNA methylation status in their non-cancerous renal cortex tissue samples was signiﬁcantly lower than that of patients in Cluster AN
(circle) (P 5 0.0000000613, Log-rank test). (C) Fifty-one patients were hierarchically clustered into two subclasses, Clusters AT (n 5 43) and BT (n 5 8), based
on the DNA methylation status of their clear cell RCCs. (D) The overall survival rate of patients in Cluster BT (square) deﬁned on the basis of DNA methylation
status in their clear cell RCCs was signiﬁcantly lower than that of patients in Cluster AT (circle) (P 5 0.0000413, Log-rank test).
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217SI (available at Carcinogenesis Online). DNA methylation status of
the 70 BAC clones, including the above 14 BAC clones, was able to
determine whether or not the patients in this cohort belonged
to Cluster BT, with a sensitivity of 100% and a speciﬁcity of 90
or .90%, using the cutoff values shown in supplementary Table SI
(available at Carcinogenesis Online).
Comparison between DNA methylation proﬁles of non-cancerous
renal tissue and those of corresponding clear cell RCC
Patients RCC1–RCC5 and patients RCC1–RCC8 were identiﬁed as
belonging to Clusters BN and BT, respectively, by unsupervised hier-
archical clustering based on BAMCA data for non-cancerous renal
cortex tissue samples and clear cell RCCs. Namely, Cluster BN
(n 5 5) was completely included in Cluster BT (n 5 8). The 724
BAC clones, the majority of the 1143 BAC clones signiﬁcantly dis-
criminating Cluster BN from Cluster AN, also discriminated Cluster
BT from Cluster AT (Wilcoxon test, P , 0.01). In 311 of the 724 BAC
clones, where the average signal ratio of Cluster BN was higher than
that of Cluster AN, the average signal ratio of Cluster BT was also
higher than that of Cluster AT without exception (Figure 3A). In 413
of the 724 BAC clones, where the average signal ratio of Cluster BN
was lower than that of Cluster AN, the average signal ratio of Cluster
BT was also lower than that of Cluster AT without exception (Figure
3A). Figure 3B shows the signal ratios of non-cancerous renal cortex
tissue samples and clear cell RCCs for all 51 patients for a represen-
tative BAC clone (RP11-44F3). In individual patients, DNA methyl-
ation status in the non-cancerous renal cortex tissue was basically
inherited by the corresponding clear cell RCC (Figure 3B).
Discussion
Many researchers in this ﬁeld use arrays in which the promoter re-
gions are enriched as probes to identify the genes methylated in can-
cer cells (8–10). However, the promoter regions of speciﬁc genes are
not the only target of DNA methylation alterations in human cancers.
DNA methylation status in genomic regions not directly participating
in gene silencing, such as the edges of CpG islands, may be altered at
the precancerous stage before the alterations of the promoter regions
themselves occur (22). Genomic regions in which DNA hypomethy-
lation affects chromosomal instability may not be contained in pro-
moter arrays. Moreover,aberrant DNA methylation of large regions of
chromosomes, which are regulated in a coordinated manner in human
cancers due to a process of long-range epigenetic silencing, has re-
cently attracted attention (23). Therefore, we used a custom-made
BAC array (16) that may be suitable, not for focusing on speciﬁc
promoter regions or individual CpG sites but for overviewing the
DNA methylation status of individual large regions among all chro-
mosomes and for subclassifying cancers by hierarchical clustering.
With respect to renal carcinogenesis, several studies of DNA meth-
ylation proﬁles of genes involved in speciﬁc signal pathways in clear
cell RCCs, such as the p53-signaling (24) and Wnt-signaling (25)
pathways, have been performed. However, to our knowledge, there
have been no published data on DNA methylation proﬁles for all
chromosomes in clear cell RCCs revealed by array-based technology.
In our previous study, we showed that samples of non-cancerous renal
cortex tissue from patients with clear cell RCC were already at the
precancerous stage with accumulation of DNA methylation on C-type
CpG islands, in spite of an absence of marked histological changes
(6,7,12). In the present study, genome-wide DNA methylation alter-
ations (both hypomethylation and hypermethylation) in samples of
non-cancerous renal cortex tissue from patients with clear cell RCC
were conﬁrmed by BAMCA (panel N of Figure 1B and C). We then
performed unsupervised hierarchical clustering analysis based on the
genome-wide DNA methylation status of the non-cancerous renal
cortex tissue samples, and as a result, 51 patients were subclassiﬁed
into Clusters AN and BN. Corresponding clear cell RCCs showing
multinodular growth, vascular involvement, renal vein tumor thrombi
and higher pathological TNM stages were found to be accumulated in
Cluster BN. Although subclassiﬁcation of precancerous tissue by unsu-
pervised hierarchical clustering analysis on the basis of genome-wide
DNA methylation proﬁles has never been performed for speciﬁc organs,
our Clusters AN and BN can be considered clinicopathologically valid.
The signiﬁcant correlation between genome-wide DNA methyla-
tion proﬁles of samples of non-cancerous renal cortex tissue and
Table I. Correlation between the subclassiﬁcation of patients based on DNA methylation status and the clinicopathological parameters of clear cell RCCs
(A) Clusters AN and BN based on DNA methylation status in non-cancerous renal cortex tissue samples
Clinicopathalogical parameters of the corresponding clear cell RCCs developing
in individual patients
Patients with clear cell RCCs P
a
Cluster AN (n 5 46) Cluster BN (n 5 5)
Macroscopic ﬁnding Type 1 26 1 0.0248
Type 2 10 0
Type 3 10 4
Vascular involvement Negative 38 0 0.0005
Positive 8 5
Renal vein tumor thrombi Negative 41 1 0.0017
Positive 5 4
Pathological TNM stage Stage I 29 0 0.0195
Stage II 1 0
Stage III 13 3
Stage IV 3 2
(B) Clusters AT and BT based on DNA methylation status in clear cell RCCs
Clinicopathalogical parameters of clear cell RCCs Patients with clear cell RCCs P
a
Cluster AT (n 5 43) Cluster BT (n 5 8)
Macroscopic ﬁnding Type 1 24 3 NS
b
Type 2 9 1
Type 3 10 4
Vascular involvement Negative 35 3 0.0297
Positive 8 5
Renal vein tumor thrombi Negative 38 4 0.0349
Positive 5 4
Pathological TNM stage Stage I 27 2 0.0263
Stage II 1 0
Stage III 13 3









218Fig. 3. (A) Scattergrams of the signal ratios in non-cancerous renal cortex tissue samples (Cluster AN versus Cluster BN) and in clear cell RCCs (Cluster AT versus
ClusterBT) onrepresentativeBAC clones,RP11-71H20, RP11-453D5,RP11-444F15, RP11-3A9andRP11-87P3.Usingthe cutoff values (CVs)describedin each
panel, patients belonging to Cluster BN were completely discriminated from patients in Cluster AN based on the DNA methylation status of non-cancerous renal
cortex tissue samples. Using the cutoff value described in each panel, patients belonging to Cluster BTwere completely discriminated from patients in Cluster AT
based on the DNA methylation status of the clear cell RCCs. When the signal ratios of Cluster BN were lower than those of Cluster AN, the signal ratios of Cluster
BTwere also lower than those of Cluster AT (RP11-71H20, RP11-453D5, RP11-444F15 and RP11-87P3). When the signal ratios of Cluster BN were higher than
those ofCluster AN, the signal ratios of Cluster BTwere also higherthanthose in Cluster AT (RP11-3A9). (B) The signal ratiosof non-cancerous renal cortextissue
(N) and clear cell RCC (T) for all 51 patients on a representative BAC clone (RP11-44F3). DNA methylation status in N was basically inherited in the
corresponding T developing in the individual patient. Gray bar, patients belonging to Cluster AT; black bar, patients belonging to Cluster BT. The case numbers of
patientsbelongingto ClusterBT (RCC1–RCC8) are also shown on the left side.Patients RCC6–RCC8didnotbelong to ClusterBN, butlatergainedthe same DNA
methylation proﬁles as those of patients RCC1–RCC5 during the development of T from N, and joined Cluster BT.
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219aggressiveness of cancers developing in individual patients indicated
that it may be possible to estimate the future risk of developing
more malignant cancers based on genome-wide DNA methylation
status at the precancerous stage. Although kidney biopsy sampling
for screening of healthy individuals is not clinically feasible because
of its invasive nature, carcinogenetic risk estimation using urine, spu-
tum and other body ﬂuid samples may be a promising approach if
optimal indicators can be identiﬁed by genome-wide DNA methyla-
tion proﬁling at the precancerous stage in the urinary tract, lung and
other organs. Patients belonging to Cluster BN showed poorer out-
come than those in Cluster AN, indicating that even patient outcome is
determined by DNA methylation status at the precancerous stage.
Although altered DNA methylation on several CpG islands has
been reported separately in RCCs (26–28), subclassiﬁcation of clear
cell RCCs, which may reﬂect the distinct epigenetic pathways of
carcinogenesis, has never been established on the basis of genome-
wide DNA methylation proﬁling. Since clear cell RCCs showing
a higher incidence of vascular involvement, renal vein tumor thrombi
and higher pathological TNM stages were accumulated in Cluster BT,
our Clusters ATand BT can be considered clinicopathologically valid.
In our previous studies, we examinedDNA methylation status on CpG
islands for the p16, hMLH 1, VHL and THBS 1 genes, and the meth-
ylated in tumor-1, -2, -12, -25 and -31 clones were examined in the
same 51 clear cell RCCs (12,29). Correlations between DNA meth-
ylation status on each CpG island and our clustering are summarized
in supplementary Table SII (available at Carcinogenesis Online). The
average number of methylated CpG islands was signiﬁcantly higher
in Cluster BT (2.75 ± 1.67) than in Cluster AT (1.54 ± 0.98,
P 5 0.01867318). Patients were considered to be positive for the
CpG island methylator phenotype when DNA methylation was seen
on three or more examined CpG islands, based on previously de-
scribed criteria (11). The frequency of CpG island methylator pheno-
type in Cluster BT (62.5%) was signiﬁcantly higher than that in
Cluster AT (16%, P 5 0.0174969). Genome-wide DNA methylation
alterations consisting of both hypomethylation and hypermethylation
of DNA revealed by BAMCA in Cluster BT are associated with re-
gional DNA hypermethylation on CpG islands and participate in ma-
lignant progression of clear cell RCCs. Moreover, patients belonging
to Cluster BT showed poorer outcome than those in Cluster AT,
indicating that prognostication of clear cell RCCs using DNA
methylation status as an indicator is a promising approach.
Some RCCs relapse and metastasize to distant organs, even if re-
section has been considered complete (17,30). Recently, immunother-
apy (31) and novel targeting agents (32) have been developed for
treatment of RCC. However, unless relapsed or metastasized tumors
are diagnosed early by close follow-up, the effectiveness of any ther-
apy is very restricted. Therefore, to assist close follow-up of patients
who have undergone nephrectomy and are still at risk of recurrence
and metastasis, prognostic indicators have been explored. Multivari-
ate analysis revealed that belonging to Cluster BT was an indepen-
dent predictor of recurrence. It is knownthat sarcomatoidRCCs with
grade 4 atypia frequently show recurrence (18). However, patients
with RCCs showing grade 1–3 atypia also suffer recurrence, and we
cannot estimate the risk of recurrence of such RCCs based on known
parameters. Belonging to Cluster BT is advantageous even to pa-
tients with RCCs showing grade 1–3 atypia because it is a predictor
of recurrence that is independent of histological grading. For clinical
application, a combination of several BAC clones from the 70 that
showed 100% sensitivity and 90 or .90% speciﬁcity (including 14
BAC clones showing 100% sensitivity and 100% speciﬁcity) can be
of optimal prognostic value for patients with clear cell RCCs. Since
a sufﬁcient quantity of good-quality DNA can be obtained from each
nephrectomy specimen, polymerase chain reaction-based analyses
focusing on individual CpG sites are not always required. Array-
based analysis that overviews aberrant DNA methylation of each
BAC region is immediately applicable to routine laboratory exami-
nations for prognostication after nephrectomy. We are currently at-
tempting to prepare a mini-array harboring some of the 70 BAC
clones. The reliability of such prognostication will need to be vali-
dated in a prospective study.
We have clariﬁed that genome-wide DNA methylation proﬁles of
non-cancerous renal cortex tissue are inherited by the corresponding
clear cell RCC based on the following ﬁndings: (i) all patients be-
longing to Cluster BN were included in Cluster BT; (ii) a majority of
the BAC clones characterizing Cluster BN (724 BAC clones) also
characterized Cluster BT; (iii) DNA methylation status on such 724
BAC clones of non-cancerous renal cortex tissue in Cluster AN was in
accordance with that of clear cell RCCs in Cluster ATand that of non-
cancerous renal cortex tissue in Cluster BN was in accordance with
that of clear cell RCCs in Cluster BT (Figure 3A) and (iv) DNA
methylation status in non-cancerous renal cortex tissue basically cor-
responded to that in the matching clear cell RCC in each patient
(Figure 3B).
Patients RCC6–RCC8 who belonged to Cluster BT but not to
Cluster BN may later gain the DNA methylation proﬁles observed
in patients RCC1–RCC5 during the establishment of clear cell RCCs
(Figure 3B) and suffer from the same degree of tumor aggressiveness
as patients RCC1–RCC5. Although alterations of DNA methylation
are considered to be involved even in the precancerous stage in
various organs (6,7,33–35), it has not yet been clariﬁed for any organ
whether DNA methylation status on only a restricted number of CpG
islands is simply altered at such stages or whether genome-wide
alterations of DNA methylation status have certain clinicopatholog-
ical signiﬁcance. The present unsupervised hierarchical clustering
revealed for the ﬁrst time that DNA methylation alterations in pre-
cancerous conditions, which may not occur randomly but are prone
to further accumulation of genetic and epigenetic alterations, can
generate more malignant cancers and even determine the ultimate
patient outcome.
Supplementary material
Supplementary Figure S1 and Tables SI and SII can be found at http://
carcin.oxfordjournals.org/
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Type 1 1 (Reference)
Type 2 5.309 (0.689–40.887) 2.570 0.1089
Type 3 0.820 (0.061–11.005) 0.022 0.8808
Vascular involvement
Negative 1 (Reference)
Positive 1.434 (0.098–20.932) 0.070 0.7920
Renal vein tumor thrombi
Negative 1 (Reference)
Positive 8.780 (0.429–179.734) 1.990 0.1584
Subclassiﬁcation based on
DNA methylation status
Cluster AT 1 (Reference)
Cluster BT 8.317 (1.100–62.901) 4.211 0.0402
CI, conﬁdence interval.
E.Arai et al.
220Innovation. Funding to pay the Open Access publication charges for
this article was provided by a Grant-in-Aid for the Third Term Com-
prehensive 10-Year Strategy for Cancer Control from the Ministry of
Health, Labor and Welfare of Japan.
Acknowledgements
Conﬂict of Interest Statement: None declared.
References
1.Jones,P.A. et al. (2002) The fundamental role of epigenetic events in can-
cer. Nat. Rev. Genet., 3, 415–428.
2.Eden,A. et al. (2003) Chromosomal instability and tumors promoted by
DNA hypomethylation. Science, 300, 455.
3.Baylin,S.B. et al. (2006) Epigenetic gene silencing in cancer—a mechanism
for early oncogenic pathway addiction? Nat. Rev. Cancer, 6, 107–116.
4.Gronbaek,K. et al. (2007) Epigenetic changes in cancer. APMIS, 115,
1039–1159.
5.Feinberg,A.P. (2007) Phenotypic plasticity and the epigenetics of human
disease. Nature, 447, 433–440.
6.Kanai,Y. et al. (2007) Alterations of DNA methylation associated with ab-
normalities of DNA methyltransferases in human cancers during transition
from a precancerous to a malignant state. Carcinogenesis, 28, 2434–2442.
7.Kanai,Y. (2008) Alterations of DNA methylation and clinicopathological
diversity of human cancers. Pathol. Int., 58, 544–558.
8.Estecio,M.R. et al. (2007) High-throughput methylation proﬁling by MCA
coupled to CpG island microarray. Genome Res., 17, 1529–1536.
9.Jacinto,F.V. et al. (2007) Discovery of epigenetically silenced genes by
methylated DNA immunoprecipitation in colon cancer cells. Cancer
Res., 67, 11481–11486.
10.Nielander,I. et al. (2007) Combining array-based approaches for the
identiﬁcation of candidate tumor suppressor loci in mature lymphoid
neoplasms. APMIS, 115, 1107–1134.
11.Toyota,M. et al. (1999) CpG island methylator phenotype in colorectal
cancer. Proc. Natl Acad. Sci. USA, 96, 8681–8686.
12.Arai,E. et al. (2006) Regional DNA hypermethylation and DNA methyl-
transferase (DNMT) 1 protein overexpression in both renal tumors and
corresponding nontumorous renal tissues. Int. J. Cancer, 119, 288–296.
13.Misawa,A. et al. (2005) Methylation-associated silencing of the nuclear
receptor 1I2 gene in advanced-type neuroblastomas, identiﬁed by bacterial
artiﬁcial chromosome array-based methylated CpG island ampliﬁcation.
Cancer Res., 65, 10233–10242.
14.Sugino,Y. et al. (2007) Epigenetic silencing of prostaglandin E receptor 2
(PTGER2) is associated with progression of neuroblastomas. Oncogene,
26, 7401–7413.
15.Tanaka,K. et al. (2007) Frequent methylation-associated silencing of a can-
didate tumor-suppressor, CRABP1, in esophageal squamous-cell
carcinoma. Oncogene, 26, 6456–6468.
16.Inazawa,J. et al. (2004) Comparative genomic hybridization (CGH)-arrays
pave the way for identiﬁcation of novel cancer-related genes. Cancer Sci.,
95, 559–563.
17.Eble,J.N. et al. (2004) Renal Cell Carcinoma. World Health Organization
Classiﬁcation of Tumours. Pathology and Genetics. Tumours of the Urinary
System and Male Genital Organs, IARC Press, Lyon, 10–43.
18.Fuhrman,S.A. et al. (1982) Prognostic signiﬁcance of morphologic param-
eters in renal cell carcinoma. Am. J. Surg. Pathol., 6, 655–663.
19.Sobin,L.H. et al. (2002) International Union Against Cancer (UICC). TNM
Classiﬁcation of Malignant Tumors, 6th edn. Wiley-Liss, New York, NY,
193–195.
20.Kanai,T. et al. (1987) Pathology of small hepatocellular carcinoma. A pro-
posal for a new gross classiﬁcation. Cancer, 60, 810–819.
21.Illingworth,R. et al. (2008) A novel CpG island set identiﬁes tissue-speciﬁc
methylation at developmental gene loci. PLoS Biol., 6, e22.
22.Maekita,T. et al. (2006) High levels of aberrant DNA methylation in
Helicobacter pylori-infected gastric mucosae and its possible association
with gastric cancer risk. Clin. Cancer Res., 12, 989–995.
23.Frigola,J. et al. (2006) Epigenetic remodeling in colorectal cancer results in
coordinate gene suppression across an entire chromosome band. Nat.
Genet., 38, 540–549.
24.Christoph,F. et al. (2006) Promoter hypermethylation proﬁle of kidney
cancer with new proapoptotic p53 target genes and clinical implications.
Clin. Cancer Res., 12, 5040–5046.
25.Urakami,S. et al. (2006) Wnt antagonist family genes as biomarkers for
diagnosis, staging, and prognosis of renal cell carcinoma using tumor and
serum DNA. Clin. Cancer Res., 12, 6989–6997.
26.Ibanez de Caceres,I. et al. (2006) Identiﬁcation of novel target genes by
an epigenetic reactivation screen of renal cancer. Cancer Res., 66,
5021–5028.
27.Costa,V.L. et al. (2007) Quantitative promoter methylation analysis of
multiple cancer-related genes in renal cell tumors. BMC Cancer, 7, 133.
28.Morris,M.R. et al. (2008) Functional epigenomics approach to identify
methylated candidate tumour suppressor genes in renal cell carcinoma.
Br. J. Cancer, 98, 496–501.
29.Arai,E. et al. (2008) Genetic clustering of clear cell renal cell carcinoma
based on array-CGH: its association with DNA methylation alteration and
patient outcome. Clin. Cancer Res., 14, 5531–5539.
30.Jones,J. et al. (2007) Genomics of renal cell cancer: the biology behind and
the therapy ahead. Clin. Cancer Res., 13, 685s–692s.
31.Guida,M. et al. (2007) Immunotherapy for metastatic renal cell carcinoma:
is it a therapeutic option yet? Ann. Oncol., 18 (suppl. 6), vi149–52.
32.Patel,P.H. et al. (2006) Targeting von Hippel-Lindau pathway in renal cell
carcinoma. Clin. Cancer Res., 12, 7215–7520.
33.Kanai,Y. et al. (1996) Aberrant DNA methylation on chromosome 16
is an early event in hepatocarcinogenesis. Jpn. J. Cancer Res., 87,
1210–1217.
34.Eguchi,K. et al. (1997) DNA hypermethylation at the D17S5 locus in non-
small cell lung cancers: its association with smoking history. Cancer Res.,
57, 4913–4915.
35.Peng,D.F. et al. (2006) DNA methylation of multiple tumor-related genes
in association with overexpression of DNA methyltransferase 1 (DNMT1)
during multistage carcinogenesis of the pancreas. Carcinogenesis, 27,
1160–1168.
Received September 1, 2008; revised November 12, 2008;
accepted November 20, 2008
DNA methylation proﬁles during renal carcinogenesis
221